These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22564985)

  • 21. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
    Leitch HA; Chan C; Leger CS; Foltz LM; Ramadan KM; Vickars LM
    Leuk Res; 2012 Nov; 36(11):1380-6. PubMed ID: 22921191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance].
    Qin Y; Liu H; Ruan S; Cai YF; You XF; Song GQ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):758-61. PubMed ID: 22339912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
    Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
    Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
    Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A
    Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S; Santini V; Musallam K; Taher A
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
    Wong SA; Leitch HA
    Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
    Malcovati L
    Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
    Hoeks M; Yu G; Langemeijer S; Crouch S; de Swart L; Fenaux P; Symeonidis A; Čermák J; Hellström-Lindberg E; Sanz G; Stauder R; Holm MS; Mittelman M; Mądry K; Malcovati L; Tatic A; Almeida AM; Germing U; Savic A; Šimec NG; Culligan D; Itzykson R; Guerci-Bresler A; Slama B; Droste J; van Marrewijk C; van de Loosdrecht A; Blijlevens N; van Kraaij M; Bowen D; de Witte T; Smith A;
    Haematologica; 2020 Mar; 105(3):640-651. PubMed ID: 31278207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].
    Zhang Y; Xiao C; Gu SC; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1027-32. PubMed ID: 25130822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
    Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
    Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.
    Hartmann J; Braulke F; Sinzig U; Wulf G; Maas JH; Konietschke F; Haase D
    Leuk Res; 2013 Mar; 37(3):327-32. PubMed ID: 23259989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital.
    Bauduer F; Recanzone H
    Transfus Clin Biol; 2020 Aug; 27(3):128-132. PubMed ID: 32561328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Tsang E; Leitch HA
    Ann Hematol; 2016 Jan; 95(1):73-78. PubMed ID: 26453076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Shammo JM; Komrokji RS
    Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.